FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W185908020> ?p ?o ?g. }

• W185908020 endingPage "9" @default.
• W185908020 startingPage "26" @default.
• W185908020 abstract "Essential thrombocythemia (ET) is a rare, chronic myeloproliferative disorder of unknown origin characterized by thrombocytosis, excessive megakaryocytes, hemorrhages, and thrombotic complications. Because of the high costs of care for persons with rare diseases, policymakers are concerned with both clinical effectiveness and cost-effectiveness of new treatments. Although the clinical efficacy of all new pharmaceutical agents for rare diseases is evaluated extensively in clinical trial settings before approval by the Food and Drug Administration (FDA), comparative phase III trials of a new agent with its major competitor are sometimes not possible to carry out, and estimates of cost-effectiveness are therefore difficult to obtain. We describe methodologic issues associated with the development of economic models of new pharmaceutical agents for rare diseases and illustrate these issues with an analysis of a new therapy for ET. Anagrelide is a newly approved platelet aggregation inhibitor that can be used as primary therapy for ET. The agent reduces platelet counts by 50% in more than 70% of ET patients. Economic models suggest that, over the first year of anagrelide therapy, monthly costs for therapy and complications decreased from $775 to $490, the effectiveness improved to 98%, and the cost-effectiveness improved to $1,505 per major complication (gastrointestinal bleed, transient ischemic attack or stroke, or preinfarction angina or myocardial infarction) prevented. Sensitivity analyses indicate that, after the first 3 months of treatment, total costs of anagrelide treatment were in the range of $1,505 to $1,615 per major complication prevented. To make well-informed therapeutic decisions, policymakers and physicians require head-to-head studies of a new pharmaceutical agent with its major competitor. However, economic models can be used to derive estimates of cost-effectiveness of new pharmaceutical agents when such data are lacking. The interpretation of these models raises general issues related to the perspective of the investigator, study design, estimation of costs of care, rates of response, toxicity, survival, and the ability to generalize the results to other settings, as well as methodologic issues that are unique to rare diseases. If a comparative study found better therapeutic outcomes, then cost-effectiveness models would be of limited usefulness. Almost all physicians would use the drug with the better therapeutic profile." @default.
• W185908020 created "2016-06-24" @default.
• W185908020 creator A5019179556 @default.
• W185908020 creator A5034676046 @default.
• W185908020 creator A5051571501 @default.
• W185908020 date "1999-01-01" @default.
• W185908020 modified "2023-10-18" @default.
• W185908020 title "Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers?" @default.
• W185908020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9930555" @default.
• W185908020 hasPublicationYear "1999" @default.
• W185908020 type Work @default.
• W185908020 sameAs 185908020 @default.
• W185908020 citedByCount "3" @default.
• W185908020 countsByYear W1859080202016 @default.
• W185908020 crossrefType "journal-article" @default.
• W185908020 hasAuthorship W185908020A5019179556 @default.
• W185908020 hasAuthorship W185908020A5034676046 @default.
• W185908020 hasAuthorship W185908020A5051571501 @default.
• W185908020 hasConcept C126322002 @default.
• W185908020 hasConcept C141071460 @default.
• W185908020 hasConcept C160735492 @default.
• W185908020 hasConcept C162324750 @default.
• W185908020 hasConcept C177713679 @default.
• W185908020 hasConcept C2776694085 @default.
• W185908020 hasConcept C2776738589 @default.
• W185908020 hasConcept C2779316324 @default.
• W185908020 hasConcept C2779703844 @default.
• W185908020 hasConcept C2779788118 @default.
• W185908020 hasConcept C2779867487 @default.
• W185908020 hasConcept C2780829020 @default.
• W185908020 hasConcept C2781057849 @default.
• W185908020 hasConcept C50522688 @default.
• W185908020 hasConcept C535046627 @default.
• W185908020 hasConcept C71924100 @default.
• W185908020 hasConcept C89560881 @default.
• W185908020 hasConceptScore W185908020C126322002 @default.
• W185908020 hasConceptScore W185908020C141071460 @default.
• W185908020 hasConceptScore W185908020C160735492 @default.
• W185908020 hasConceptScore W185908020C162324750 @default.
• W185908020 hasConceptScore W185908020C177713679 @default.
• W185908020 hasConceptScore W185908020C2776694085 @default.
• W185908020 hasConceptScore W185908020C2776738589 @default.
• W185908020 hasConceptScore W185908020C2779316324 @default.
• W185908020 hasConceptScore W185908020C2779703844 @default.
• W185908020 hasConceptScore W185908020C2779788118 @default.
• W185908020 hasConceptScore W185908020C2779867487 @default.
• W185908020 hasConceptScore W185908020C2780829020 @default.
• W185908020 hasConceptScore W185908020C2781057849 @default.
• W185908020 hasConceptScore W185908020C50522688 @default.
• W185908020 hasConceptScore W185908020C535046627 @default.
• W185908020 hasConceptScore W185908020C71924100 @default.
• W185908020 hasConceptScore W185908020C89560881 @default.
• W185908020 hasIssue "1 Suppl 2" @default.
• W185908020 hasLocation W1859080201 @default.
• W185908020 hasOpenAccess W185908020 @default.
• W185908020 hasPrimaryLocation W1859080201 @default.
• W185908020 hasRelatedWork W185908020 @default.
• W185908020 hasRelatedWork W1961273556 @default.
• W185908020 hasRelatedWork W2027519412 @default.
• W185908020 hasRelatedWork W2035199759 @default.
• W185908020 hasRelatedWork W2039687934 @default.
• W185908020 hasRelatedWork W2090084912 @default.
• W185908020 hasRelatedWork W2125468777 @default.
• W185908020 hasRelatedWork W2571034276 @default.
• W185908020 hasRelatedWork W2603252551 @default.
• W185908020 hasRelatedWork W3036235512 @default.
• W185908020 hasVolume "36" @default.
• W185908020 isParatext "false" @default.
• W185908020 isRetracted "false" @default.
• W185908020 magId "185908020" @default.
• W185908020 workType "article" @default.